Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team
April 24 2017 - 7:00AM
Business Wire
Key additions and promotions to team in
commercial, development and regulatory roles
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced the appointment of Michael Cloonan as Chief Business
Officer. Additional executive appointments include Christopher
Silber, M.D., as Senior Vice President, Clinical Development, Paul
Hodgkins, Ph.D., as Vice President, Health Economics and Outcomes
Research and Value Demonstration and Frank Sanders as Vice
President, Sales & Marketing. In addition, Amy Schacterle,
Ph.D., has been promoted to Senior Vice President, Regulatory
Affairs and Quality Assurance.
“I am pleased to welcome Michael Cloonan, a highly-respected and
very accomplished biopharmaceutical executive, to our team. In this
new leadership role, Mike will be responsible for planning and
executing an integrated global commercial strategy,” said Jeff
Jonas, M.D., Chief Executive Officer of Sage Therapeutics. “We are
excited to continue our buildout of critical leadership roles
across the organization as we progress our broadening clinical
pipeline across multiple CNS disorders, and plan for potential
product commercialization next year. Mike, Chris, Paul and Frank
add new capabilities and expertise to our team as we continue to
evolve into a leading CNS company.”
Michael Cloonan will lead Sage’s Commercial, Portfolio and
Program Management, Medical Affairs, and Corporate Development
departments. Mr. Cloonan comes to Sage from Biogen, where he worked
for 14 years. At Biogen, Mr. Cloonan most recently served as Senior
Vice President, US Commercial, where he led a US affiliate with
direct general manager responsibility for Sales, Marketing, Market
Access, Patient Services and Commercial Operations. Previously, he
held roles of increasing responsibility at Biogen, including Senior
Vice President, Global Commercial Strategy; Vice President,
Managing Director, Australia/New Zealand affiliate; and Vice
President, Business Planning. Prior to Biogen, Mr. Cloonan worked
at Bain & Company as a consultant specializing in healthcare.
Mr. Cloonan received his M.B.A. from Darden Graduate School of
Business Administration, University of Virginia and a B.A. from
College of the Holy Cross.
Chris Silber, M.D., is an experienced drug development leader
with over 25 years in executive roles in the pharmaceutical
industry. Dr. Silber will lead the Medical Science, Clinical
Operations and Data Science departments at Sage and will play a key
role in clinical trial design and clinical program planning and
execution. Prior to Sage, Dr. Silber served most recently as Chief
Medical Officer for Agilis Biotherapeutics having previously held
various clinical leadership roles at H. Lundbeck A/S for seven
years, including Vice President, US Clinical Development Center and
Vice President, US Clinical Research and Medical Affairs. Before
Lundbeck, Dr. Silber held clinical research and drug development
management roles at Takeda, Hospira, and Abbott Laboratories. Dr.
Silber holds an M.D. from S.U.N.Y. at Buffalo School of Medicine
and a B.A. in Psychology from Tufts University.
Paul Hodgkins, Ph.D., joins Sage from Vertex, where he served as
Vice President, Global Health Economics & Outcomes Research
since 2013. Prior to Vertex, Dr. Hodgkins held roles at Shire
Pharmaceuticals including Senior Director, Global Health Economics
Outcomes Research and Senior Global Medical Affairs Director. Dr.
Hodgkins holds a BSc in Biochemistry, Pharmacology, and Statistics
from the University of Wolverhampton, a Ph.D. in Neuroscience from
Aston University, and an MSc in Health Economics and Management
from the University of Sheffield.
Frank Sanders joins Sage with over 20 years of experience in the
biopharmaceutical industry. Mr. Sanders will have responsibility
for the development of marketing strategies and market growth
plans, along with account management execution for the US market.
Most recently, Mr. Sanders served as Vice President, Strategic
Account Management at Janssen Pharmaceutical Companies of Johnson
& Johnson. Previously, Mr. Sanders held a wide range of senior
leadership roles for GlaxoSmithKline, including Vice President,
Marketing, Customer Strategy and Vice President, Field Sales. Mr.
Sanders holds a B.A. in Business Administration from Wittenberg
University.
Amy Schacterle, Ph.D., has been at Sage since 2014. She has led
Sage's successful interactions with global regulatory authorities
and has overseen the filing of several Investigational New Drug
(IND) applications. In addition, Dr. Schacterle has led Sage's
efforts in accelerating its development programs through regulatory
initiatives, such as obtaining Breakthrough Therapy and PRIority
MEdicines (PRIME) designations for Sage's Phase 3 program for
postpartum depression.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders.
Sage has a portfolio of novel product candidates targeting critical
CNS receptor systems, GABA and NMDA. Sage's lead program,
brexanolone (SAGE-547), is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure
disorder, and for postpartum depression. Sage is developing its
next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please visit
www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170424005510/en/
Investors:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia:Suda Communications
LLCMaureen L. Suda, 585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024